Retatrutide is an investigational once-weekly injection from Eli Lilly that activates three hormone receptors (GIP, GLP-1, and glucagon). In Phase 3 trials, adults taking the highest dose lost an average of roughly 21% to 25% of their body weight at 80 weeks, depending on the population and how the results were analyzed (reference 1). It is not FDA-approved, Lilly says it plans to submit an application in the first quarter of 2027, and Lilly states it cannot be legally sold or marketed for human use (reference 1). This guide covers how it works, what the trials do and don't show, the side effects reported so far, and why "research-grade" retatrutide sold online is dangerous.
At a Glance
- Status (October 2026): Investigational. Not approved by the FDA or any major regulator. Lilly plans a U.S. submission in Q1 2027 (reference 1), and no decision date has been set.
- Mechanism: One molecule that activates GIP, GLP-1, and glucagon receptors. Semaglutide targets GLP-1 alone, and tirzepatide targets GLP-1 and GIP.
- Efficacy: Large average weight loss versus placebo in Phase 3, but averages hide a wide range of individual responses.
- Safety: Mostly digestive side effects so far, plus a signal of abnormal skin sensations (dysesthesia). Long-term safety is unknown.
- Do not buy it online. Products sold as research peptides are unregulated, and what is in the vial is unknown.
How Retatrutide Works
| Receptor | Proposed role | Confidence |
|---|---|---|
| GLP-1 | Reduces appetite, slows stomach emptying, and raises insulin release when glucose is high | Well established from approved drugs |
| GIP | Works with GLP-1 on insulin signaling and may affect appetite and fat metabolism | Moderate. Exact contribution is still debated. |
| Glucagon | May increase energy expenditure and fat burning, including in the liver | Plausible, with less human evidence than the other two |
The idea is that combining the signals produces more weight loss than hitting one or two. That is a hypothesis supported by the trial results, not proof of how each receptor contributes.
What the Trials Show
| Trial | Who | Result at 12 mg (vs. placebo) |
|---|---|---|
| Phase 2 (2023) | 338 adults with obesity or overweight | Up to about 24% at 48 weeks. This was the study the original draft described. |
| TRIUMPH-1 | 2,339 adults with obesity or overweight, without diabetes | 80 weeks: 28.3% vs 2.2% in Lilly's topline efficacy analysis (reference 2). In the published analysis counting everyone randomized, 25.0% vs 3.9%. |
| TRIUMPH-2 | 1,152 adults with obesity and type 2 diabetes | 80 weeks: 20.8% vs 4.0% (efficacy analysis), with A1C reductions of up to 1.6 percentage points (reference 1) |
| TRIUMPH-3 | 1,949 adults with severe obesity and established cardiovascular disease | 80 weeks: up to 22.6% vs 3.2% (efficacy analysis) (reference 1) |
| TRIUMPH-4 | Adults with obesity and knee osteoarthritis | Up to 28.7% at 68 weeks, as reported by Lilly |
How to read these numbers
- Two ways of counting: The "efficacy" analysis estimates results if everyone stayed on treatment. The "treatment-regimen" analysis counts everyone randomized, including people who stopped. The first is higher, and both are valid, but they answer different questions.
- Averages are not promises. Individual results varied widely. Some people lost much less.
- Weight loss levels off. In TRIUMPH-1, curves for the higher doses flattened late in the trial, so loss does not continue indefinitely.
- Company results come first. Several results above were first reported in press releases. Wait for peer-reviewed publication and independent analysis before drawing conclusions.
- Heart outcomes are not proven. TRIUMPH-3 was not designed to show a reduction in heart events, and the difference observed was statistically uncertain (reference 1). A dedicated outcomes trial is underway.
Side Effects Reported So Far
| Effect (TRIUMPH-2 and 3, retatrutide vs. placebo) | Reported frequency |
|---|---|
| Diarrhea | About 24% to 34% vs 9% to 13% |
| Nausea | About 14% to 28% vs 6% to 8% |
| Constipation | About 14% to 18% vs 7% to 9% |
| Decreased appetite | About 6% to 17% vs 3% to 5% |
| Vomiting | About 6% to 16% vs 4% (TRIUMPH-2) |
| Dysesthesia (abnormal skin sensations) | About 4.5% to 7.3% vs 0.7% (TRIUMPH-2); 6.4% vs 1.3% (TRIUMPH-3) |
| Stopped treatment because of side effects | 9.8% to 13.5% vs 4.8% (TRIUMPH-3) |
Source for all rows: Lilly's July 2026 announcement (reference 1). Lilly describes the events as generally mild to moderate, with most resolving during treatment. Digestive effects increased with dose.
What is not yet known: Long-term safety, rare effects, and how retatrutide affects people outside strict trial criteria. Approved drugs in the same family carry warnings for pancreatitis, gallbladder problems, dehydration with kidney injury, low blood sugar when used with insulin or sulfonylureas, vision changes in people with diabetes, and, in animals, thyroid C-cell tumors (reference 1, from Zepbound's safety summary). How these apply to retatrutide is still being studied. Do not assume it is free of them.
Why You Should Not Buy It Online
Retatrutide has no approved prescription pathway. Products sold online as "research peptides" are made outside regulatory oversight, and a vial may contain the wrong amount, a different substance, or contamination. Self-injecting also removes the monitoring trial participants receive. Because the trials escalated doses stepwise under medical supervision, trial doses are not a guide for self-use.
| Symptom after injecting an unregulated product | What to do |
|---|---|
| Severe, persistent abdominal pain, with or without vomiting | Seek urgent care. It could signal pancreatitis or gallbladder problems. |
| Ongoing vomiting or diarrhea, dizziness, very little urine | Seek care for dehydration, which can injure the kidneys |
| Fever, spreading redness, or pus at the injection site | Seek same-day care |
| Yellowing of skin or eyes, or clay-colored stools | Seek urgent care |
| Facial or throat swelling, trouble breathing, severe rash | Call emergency services |
| Shakiness, sweating, confusion (low blood sugar, especially if you take diabetes medicine) | Treat low blood sugar and get medical help |
If you have already used an unregulated product, tell a clinician exactly what you took. They are there to help, not judge.
If You Want Treatment Now
Approved options exist, and a clinician can help decide whether one fits your health history. Check each product's current label, since indications change.
| Medication | Mechanism | Notes |
|---|---|---|
| Semaglutide (Wegovy, Ozempic) | GLP-1 | Wegovy is approved for weight management and Ozempic for type 2 diabetes |
| Tirzepatide (Zepbound, Mounjaro) | GLP-1 and GIP | Zepbound is approved for obesity and for obstructive sleep apnea in adults with obesity (reference 1). Mounjaro is for type 2 diabetes. |
| Orforglipron (Foundayo) | Oral GLP-1 | Daily tablet for adults with obesity or overweight with related conditions (reference 1) |
Comparisons between drugs from separate trials cannot show which works best, because the populations, durations, and analyses differ.
Protecting Muscle During Weight Loss
This applies to any weight-loss medication. A meaningful share of weight lost can be lean mass, not only fat. For lifters and active people, the practical response is resistance training on two or more days a week, which matches U.S. guidelines for muscle-strengthening activity (reference 4), enough protein, and checking strength and body composition over time. Ask your clinician or a dietitian for a protein target that fits your health, especially with kidney disease. This is general guidance, not a retatrutide-specific finding.
What to Watch Next
- Lilly says it plans to submit a Biologics License Application to the FDA in Q1 2027 for obesity, with further submissions planned for knee osteoarthritis pain and obstructive sleep apnea (reference 1).
- No approval date has been set. Estimates you see online are speculation.
- Long-term outcomes trials on heart and kidney events are ongoing.
Frequently Asked Questions
Is retatrutide FDA-approved?
No. Lilly plans to submit an application in Q1 2027, and the FDA has not made a decision.
How much weight did people lose?
At 80 weeks on the highest dose, about 21% to 28% on average depending on the trial and how results were analyzed, compared with a few percent on placebo. Individual results varied.
How does it differ from tirzepatide?
Tirzepatide activates GLP-1 and GIP receptors. Retatrutide adds glucagon receptor activation.
What are the main side effects?
Digestive effects such as diarrhea, nausea, constipation, and vomiting, plus a signal of abnormal skin sensations. Long-term safety is unknown.
Is it safe to buy retatrutide online?
No. It cannot be legally sold or marketed for human use, and unregulated products may be mislabeled, contaminated, or not contain the drug.
References
- Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials (TRIUMPH-2 and TRIUMPH-3). July 23, 2026. prnewswire.com
- The Pharmaceutical Journal. Phase III retatrutide study demonstrates 30% weight loss (TRIUMPH-1 topline). May 2026. pharmaceutical-journal.com
- Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine, 2023.
- U.S. Department of Health and Human Services. Physical Activity Guidelines for Americans, 2nd edition (executive summary). health.gov
This article is general educational information and not a substitute for personal medical advice.
